Can pyridostigmine cross the blood-brain barrier? A detailed pharmacological analysis
•
4 min read
Pyridostigmine's quaternary ammonium structure is the primary reason it does not readily cross the intact blood-brain barrier under normal physiological conditions, making its effects largely peripheral. This critical pharmacological detail explains its therapeutic utility in diseases like myasthenia gravis and why it differs significantly from other cholinesterase inhibitors.
